Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) (RAPID STEMI)

This study has been completed.
Sponsor:
Collaborator:
Spartan Bioscience Inc.
Information provided by (Responsible Party):
Derek So, University of Ottawa Heart Institute
ClinicalTrials.gov Identifier:
NCT01452139
First received: September 27, 2011
Last updated: April 23, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2013
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)